4/28/2023 0 Comments Medavante prophase(Image: iStock/ktsimage) WIRB-Copernicus Group (WCG) has acquired MedAvante and ProPhase, bolstering the company’s presence in the central nervous system (CNS) and behavioral health assessment markets. “Combining the strengths of MedAvante and ProPhase with the expansive clinical research expertise and global reach of WCG will provide expertise for those conducting clinical trials in the fields of CNS and mental health,” said Litwin.įor more background information on Litwin, see an earlier appointment reported by Manufacturing Chemist. MedAvante is a clinical data services company and ProPhase provides measurement-related solutions for clinical trials. No portion of this program may be used for any purpose or transferred or reproduced in any form or by any means without the prior written permission of. They cover business area such as provider, centralized clinical rating service, psychiatric and neurocognition rating, monitoring service, an investigative study platform, site-base assessment. Neither this program nor the information contained in this program may be disclosed to any third party. MedAvante-ProPhase is Monitoring Equipment in United States that focus on monitoring services business. WCG will provide corporate support to these two organisations as they continue to expand, with access to capital, and complementary clinical and regulatory expertise. Supported by operations teams in the US, Germany, Russia and Japan, MedAvante-ProPhase delivers services for clinical trials in more than 40 countries worldwide. This program is the confidential and proprietary product of MedAvante. The acquisition of MedAvante and ProPhase positions WCG in central nervous system (CNS) scene and behavioral health assessment markets, through the delivery of clinical services and technology solutions that improve signal detection. WIRB-Copernicus Group (WCG), provider of solutions to improve the quality and efficiency of clinical research, has acquired MedAvante and ProPhase, and has named Jeffrey Litwin as the CEO of the combined organisation. MedAvante-ProPhase employees rate the overall compensation and benefits package 3.7/5 stars. Names Jeffrey Litwin as the Chief Executive Officer (CEO) of the combined company To complete the assessment open the application in the: Chrome version 88 and up Edge version 79 and up.version 79 and up. The average MedAvante-ProPhase salary ranges from approximately 110,245 per year for a Project Manager to 138,391 per year for a Senior Project Manager.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |